No Data
Express News | Zhejiang Huahai Pharmaceutical: Subsidiary obtains drug clinical trial license.
Overseas income sharply decreased, impacting performance, and the funding projects of Otaibio have been delayed.
① Due to the impact of international situations, economic policies, and fluctuations in the overall market, the fundraising projects of Aotai Biological aimed at expanding overseas markets will be delayed. ② Overseas revenue has always been the most core source of income for Aotai Biological, with the overall income proportion once reaching 99.83%, and the sharp decline in overseas revenue has also led to a significant drop in Aotai Biological's overall income.
Express News | Zhejiang Huahai Pharmaceutical: The first subject in New Zealand to be dosed with the TSLP/IL-11 bispecific monoclonal antibody independently developed by its subsidiary.
Express News | Zhejiang Huahai Pharmaceutical: Subsidiary HB56 injection granted clinical trial approval in New Zealand.
Aotec Pharma (688606) 2024 Third Quarterly Report Review: Small but excellent POCT leader, continuous improvement in operational situation.
Key Investment Events: On October 30, 2024, the company released its third-quarter report for 2024. In the third quarter alone, the company achieved revenue of 0.222 billion yuan, a year-on-year increase of 28.72%, with a net income attributable to shareholders of 0.74.
Aotai Biotech: Third quarter report 2024
